Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Aegon ( (AEG) ) has issued an update.
On May 8, 2025, Aegon announced the agenda for its Annual General Meeting of Shareholders scheduled for June 12, 2025. The meeting will present the 2024 Annual Accounts and propose a final dividend of EUR 0.19 per common share, totaling EUR 0.35 for 2024. The AGM will be held in Bermuda in a hybrid format, allowing shareholders to attend in person or virtually, with opportunities to ask questions and vote in advance. This meeting is significant for stakeholders as it addresses dividend proposals and board composition changes, impacting Aegon’s operations and strategic direction.
Spark’s Take on AEG Stock
According to Spark, TipRanks’ AI Analyst, AEG is a Neutral.
Aegon shows recovery in profitability and strategic growth, particularly in the U.S. and U.K., with strong asset management results. The stock’s valuation is reasonable, supported by a robust dividend yield. However, challenges such as equity retention, market sensitivity, and segment-specific issues temper the overall positive outlook.
To see Spark’s full report on AEG stock, click here.
More about Aegon
Aegon is an international financial services holding company that provides investment, protection, and retirement solutions. It operates fully owned businesses in the United States and United Kingdom, and has a global asset manager. Aegon also engages in insurance joint-ventures in Spain, Portugal, China, and Brazil, and asset management partnerships in France and China. The company is headquartered in The Hague, Netherlands, domiciled in Bermuda, and listed on Euronext Amsterdam and the New York Stock Exchange.
Average Trading Volume: 10,211,202
Technical Sentiment Signal: Strong Buy
Current Market Cap: $10.36B
Find detailed analytics on AEG stock on TipRanks’ Stock Analysis page.